Clarius Group LLC Grows Stock Position in Zoetis Inc. $ZTS

Clarius Group LLC grew its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 6.3% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,554 shares of the company’s stock after purchasing an additional 268 shares during the quarter. Clarius Group LLC’s holdings in Zoetis were worth $710,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the stock. Nuveen LLC bought a new position in Zoetis in the 1st quarter worth approximately $616,375,000. Mackenzie Financial Corp boosted its position in shares of Zoetis by 4,158.3% during the 1st quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company’s stock valued at $300,481,000 after acquiring an additional 1,782,110 shares during the last quarter. Sarasin & Partners LLP bought a new position in shares of Zoetis during the 1st quarter valued at approximately $255,842,000. Polen Capital Management LLC raised its holdings in Zoetis by 17.6% during the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after buying an additional 1,313,653 shares during the period. Finally, Amundi raised its holdings in Zoetis by 30.8% during the 1st quarter. Amundi now owns 3,595,628 shares of the company’s stock valued at $575,691,000 after buying an additional 846,909 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on ZTS. Piper Sandler increased their price target on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Argus restated a “buy” rating and set a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Stifel Nicolaus lowered Zoetis from a “buy” rating to a “hold” rating and decreased their price target for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partners lowered Zoetis from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Finally, Leerink Partnrs lowered Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Five investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $200.88.

Zoetis Stock Performance

ZTS stock opened at $146.45 on Monday. The firm has a market cap of $64.91 billion, a price-to-earnings ratio of 25.21, a PEG ratio of 2.35 and a beta of 0.90. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a twelve month low of $139.34 and a twelve month high of $196.55. The business’s fifty day simple moving average is $149.79 and its two-hundred day simple moving average is $155.02.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.62 by $0.14. The firm had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same quarter last year, the firm posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.